AU2004206856B9 - Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions - Google Patents

Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions Download PDF

Info

Publication number
AU2004206856B9
AU2004206856B9 AU2004206856A AU2004206856A AU2004206856B9 AU 2004206856 B9 AU2004206856 B9 AU 2004206856B9 AU 2004206856 A AU2004206856 A AU 2004206856A AU 2004206856 A AU2004206856 A AU 2004206856A AU 2004206856 B9 AU2004206856 B9 AU 2004206856B9
Authority
AU
Australia
Prior art keywords
capture
group
drug
biomolecules
moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004206856A
Other languages
English (en)
Other versions
AU2004206856C1 (en
AU2004206856A1 (en
AU2004206856B2 (en
AU2004206856A8 (en
Inventor
Matthew Peter Grealish
Chester Frederick Hassman Iii
Hubert Koster
Daniel Paul Little
Subramanian Marappan
Suhaib Mahmood Siddiqi
Ping Yip
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
caprotec bioanalytics GmbH
Original Assignee
caprotec bioanalytics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by caprotec bioanalytics GmbH filed Critical caprotec bioanalytics GmbH
Publication of AU2004206856A1 publication Critical patent/AU2004206856A1/en
Assigned to KOSTER, HUBERT reassignment KOSTER, HUBERT Request for Assignment Assignors: HK PHARMACEUTICALS, INC., KOSTER, HUBERT
Publication of AU2004206856C1 publication Critical patent/AU2004206856C1/en
Publication of AU2004206856B2 publication Critical patent/AU2004206856B2/en
Publication of AU2004206856A8 publication Critical patent/AU2004206856A8/en
Application granted granted Critical
Publication of AU2004206856B9 publication Critical patent/AU2004206856B9/en
Priority to AU2006249219A priority Critical patent/AU2006249219B2/en
Assigned to CAPROTEC BIOANALYTICS GMBH reassignment CAPROTEC BIOANALYTICS GMBH Request for Assignment Assignors: KOSTER, HUBERT
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/96—Esters of carbonic or haloformic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/12—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/14—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by free hydroxyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/16—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by esterified hydroxyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D317/34—Oxygen atoms
    • C07D317/36—Alkylene carbonates; Substituted alkylene carbonates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrrole Compounds (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2004206856A 2003-01-16 2004-01-16 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions Ceased AU2004206856B9 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2006249219A AU2006249219B2 (en) 2003-01-16 2006-12-06 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44139803P 2003-01-16 2003-01-16
US60/441,398 2003-01-16
PCT/US2004/001037 WO2004064972A2 (en) 2003-01-16 2004-01-16 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2006249219A Division AU2006249219B2 (en) 2003-01-16 2006-12-06 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions

Publications (5)

Publication Number Publication Date
AU2004206856A1 AU2004206856A1 (en) 2004-08-05
AU2004206856C1 AU2004206856C1 (en) 2006-09-07
AU2004206856B2 AU2004206856B2 (en) 2006-09-07
AU2004206856A8 AU2004206856A8 (en) 2006-09-07
AU2004206856B9 true AU2004206856B9 (en) 2006-11-02

Family

ID=32771925

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004206856A Ceased AU2004206856B9 (en) 2003-01-16 2004-01-16 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions

Country Status (11)

Country Link
US (3) US20060051879A9 (enExample)
EP (2) EP1583972B1 (enExample)
JP (2) JP4741458B2 (enExample)
AT (1) ATE489629T1 (enExample)
AU (1) AU2004206856B9 (enExample)
CA (2) CA2658334C (enExample)
DE (1) DE602004030212D1 (enExample)
DK (1) DK2259068T3 (enExample)
IL (3) IL169437A (enExample)
SG (1) SG153699A1 (enExample)
WO (1) WO2004064972A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3935487B2 (ja) 2001-07-16 2007-06-20 フーベルト・ケスター 捕獲化合物、その収集物、ならびにプロテオームおよび複合組成物の分析方法
EP1502102B1 (en) * 2002-03-11 2009-01-14 caprotec bioanalytics GmbH Compounds and methods for analyzing the proteome
ATE489629T1 (de) * 2003-01-16 2010-12-15 Caprotec Bioanalytics Gmbh Verfahren zur identifizierung von auf arzneimittel nicht-zielgerichteten proteinen
US20060210982A1 (en) * 2003-01-31 2006-09-21 Hiroshi Yanagawa Cleavable assigned molecules and screening method using the same
EP1800136B1 (en) * 2004-10-15 2011-12-07 Danisco US Inc. Competitive differential screening
GB0515323D0 (en) * 2005-07-26 2005-08-31 Electrophoretics Ltd Mass labels
US7837626B2 (en) * 2005-08-05 2010-11-23 Siemens Medical Solutions Usa, Inc. Contrast agent manipulation with medical ultrasound imaging
ES2397441T5 (es) 2006-02-13 2022-09-14 Daiichi Sankyo Co Ltd Secuencias polinucleotídicas y polipeptídicas implicadas en el proceso de remodelación ósea
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
US8084734B2 (en) * 2006-05-26 2011-12-27 The George Washington University Laser desorption ionization and peptide sequencing on laser induced silicon microcolumn arrays
US20080017512A1 (en) * 2006-07-24 2008-01-24 Bordunov Andrei V Coatings for capillaries capable of capturing analytes
US8110796B2 (en) 2009-01-17 2012-02-07 The George Washington University Nanophotonic production, modulation and switching of ions by silicon microcolumn arrays
US8268264B2 (en) * 2009-02-09 2012-09-18 Caprotec Bioanalytics Gmbh Devices, systems and methods for separating magnetic particles
US20100281003A1 (en) * 2009-04-02 2010-11-04 New York University System and uses for generating databases of protein secondary structures involved in inter-chain protein interactions
US9490113B2 (en) 2009-04-07 2016-11-08 The George Washington University Tailored nanopost arrays (NAPA) for laser desorption ionization in mass spectrometry
GB0916881D0 (en) * 2009-09-25 2009-11-11 Electrophoretics Ltd Mass labels
GB201014023D0 (en) 2010-08-20 2010-10-06 Ucl Business Plc Process for producing bioconjugates and products thereof
DE102010060498B4 (de) 2010-11-11 2013-04-18 Caprotec Bioanalytics Gmbh Isolierung und funktionale Identifizierung ganzer Zellen
DE102011050363A1 (de) 2011-05-13 2012-11-15 Caprotec Bioanalytics Gmbh Stufenweise aufbaubare Fängerverbindungen und Verfahren zur Proteinisolierung aus komplexen Gemischen
CA2864080C (en) 2012-02-07 2023-04-25 Vibrant Holdings, Llc Substrates, peptide arrays, and methods
EP2821489B1 (en) * 2012-03-02 2017-02-22 Japan Science And Technology Agency Method for constructing functional nucleic acid molecule, and nucleic acid combination to be used in said method
US9354237B2 (en) * 2012-05-18 2016-05-31 Purdue Research Foundation Methods for isolating proteins
US9493562B2 (en) 2012-07-19 2016-11-15 Alethia Biotherapeutics Inc. Anti-Siglec-15 antibodies
DE102012216346A1 (de) 2012-09-13 2014-03-13 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zum Markieren oder Immobilisieren einer Zielstruktur
US10006909B2 (en) 2012-09-28 2018-06-26 Vibrant Holdings, Llc Methods, systems, and arrays for biomolecular analysis
US10286376B2 (en) 2012-11-14 2019-05-14 Vibrant Holdings, Llc Substrates, systems, and methods for array synthesis and biomolecular analysis
EP2913674A1 (en) 2014-02-28 2015-09-02 Caprotec Bioanalytics GmbH Stepwise assembled capture compounds comprising a cleavable function and method for isolating and/or characterizing biomolecules or biomolecule fragments, in particular proteins or protein fragments, of complex mixtures
CN104483445B (zh) * 2014-12-03 2016-10-12 广东省食品药品检验所 一种噻唑烷二酮快速检测试剂盒及其检测方法
JP6920206B2 (ja) * 2015-03-12 2021-08-18 ヴィブラント ホールディングス リミテッド ライアビリティ カンパニー ポリペプチドアレイおよびポリペプチドをアレイに取り付ける方法
WO2017029194A1 (en) * 2015-08-14 2017-02-23 Johannes Kepler Universität Linz Regenerative biosensor
WO2018143357A1 (ja) * 2017-02-01 2018-08-09 国立大学法人浜松医科大学 標的物質と親和性の高い物質をスクリーニングする方法
CN110325491B (zh) * 2017-03-17 2022-04-19 成都先导药物开发股份有限公司 编码库的合成方法及组合物
CN107102079A (zh) * 2017-04-26 2017-08-29 苏州海科医药技术有限公司 检测人血浆中阿托伐他汀及代谢物的液相色谱‑串联质谱方法及临床药动学研究的应用
AU2018356642A1 (en) * 2017-10-26 2020-04-30 Commissariat A L'energie Atomique Et Aux Energies Alternatives Methods and pharmaceutical compositions for treating tubulin carboxypeptidases associated diseases
CN108061777B (zh) * 2017-11-27 2020-05-08 浙江公正检验中心有限公司 减肥类保健食品中34种非法添加药物残留量的检测方法
EP3729090A4 (en) * 2017-12-22 2021-09-22 Pacific Biosciences Of California, Inc. IMMOBILIZATION MODIFIED BIOTIN BINDING PROTEINS
US20220081400A1 (en) * 2018-07-16 2022-03-17 The Scripps Research Institute Opioid haptens, conjugates, vaccines, and methods of generating antibodies
CN109682912A (zh) * 2019-01-16 2019-04-26 徐州立兴佳正医药科技有限公司 一种液质联用测定血浆中塞来昔布浓度的方法
DE102019109771B4 (de) * 2019-04-12 2022-06-30 Bruker Daltonics GmbH & Co. KG Auswertung komplexer Massenspektrometrie-Daten von biologischen Proben
WO2020261221A1 (en) * 2019-06-26 2020-12-30 Waters Technologies Corporation Coatings with immobilized affinity ligands and enzymes and use thereof in liquid chromatography assays
CN116829922A (zh) * 2020-12-17 2023-09-29 豪夫迈·罗氏有限公司 用于质谱法的基于蒸发的样品制备工作流程
CN114112980B (zh) * 2022-01-24 2022-05-10 武汉宏韧生物医药股份有限公司 一种基于数据分析的药物组分检测方法与系统
CN116136595B (zh) * 2023-02-24 2025-09-30 西安电子科技大学 基于两级尺度微调的协同探测双基前视sar成像处理方法

Family Cites Families (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4415732A (en) * 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US5198540A (en) * 1982-10-28 1993-03-30 Hubert Koster Process for the preparation of oligonucleotides in solution
DE3239887A1 (de) 1982-10-28 1984-05-03 Hubert Prof. Dr. 2000 Hamburg Köster Verfahren zur herstellung von oligonucleotiden
DE3239888A1 (de) 1982-10-28 1984-05-03 Hubert Prof. Dr. 2000 Hamburg Köster Verfahren zur herstellung von oligonucleosidphosphonaten
DE3326520A1 (de) 1983-07-22 1985-01-31 Hubert Prof. Dr. 2000 Hamburg Köster Verfahren zur definierten verknuepfung doppelhelikaler dna-fragmente mittels einer linker-dna sowie als linker-dna geeignete oligonucletide
DE3329892A1 (de) 1983-08-18 1985-03-07 Köster, Hubert, Prof. Dr., 2000 Hamburg Verfahren zur herstellung von oligonucleotiden
DE3537403C2 (de) * 1985-10-21 1995-06-01 Papst Motoren Gmbh & Co Kg Kollektorloser Gleichstrommotor mit oder für einen Lüfter
EP0285675A1 (de) 1987-02-06 1988-10-12 BIOSYNTECH Biochemische Synthesetechnik GmbH Synthetische DNA-Kassetten mit Kodierung fuer artifizielle Proteine und deren Expression
US4923901A (en) 1987-09-04 1990-05-08 Millipore Corporation Membranes with bound oligonucleotides and peptides
EP0310361A3 (en) * 1987-09-30 1989-05-24 Beckman Instruments, Inc. Tridentate conjugate and method of use thereof
JPS6455181U (enExample) 1987-09-30 1989-04-05
US5770625A (en) * 1988-02-08 1998-06-23 The Trustees Of Columbia University In The City Of New York Butyryl-tyrosinyl spermine, analogs thereof and methods of preparing and using same
US5011861A (en) 1988-06-28 1991-04-30 Millipore Corporation Membranes for solid phase protein sequencing
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5547839A (en) * 1989-06-07 1996-08-20 Affymax Technologies N.V. Sequencing of surface immobilized polymers utilizing microflourescence detection
JPH04178394A (ja) * 1989-09-22 1992-06-25 Mitsui Toatsu Chem Inc イノシトール誘導体およびその製法
US5410068A (en) * 1989-10-23 1995-04-25 Perseptive Biosystems, Inc. Succinimidyl trityl compounds and a process for preparing same
US5723286A (en) * 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
CZ49693A3 (en) * 1990-09-24 1994-02-16 Gen Hospital Corp Method for testing of a compound capability to inhibit onco-protein activity
WO1994010300A1 (en) * 1992-10-30 1994-05-11 The General Hospital Corporation Interaction trap system for isolating novel proteins
US6436635B1 (en) * 1992-11-06 2002-08-20 Boston University Solid phase sequencing of double-stranded nucleic acids
US6194144B1 (en) * 1993-01-07 2001-02-27 Sequenom, Inc. DNA sequencing by mass spectrometry
ATE267877T1 (de) * 1993-01-07 2004-06-15 Sequenom Inc Dns - sequenzierung durch massenspektronomie
US5605798A (en) * 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
US5512473A (en) * 1993-01-29 1996-04-30 Brent; Roger Max-interacting proteins and related molecules and methods
US6074823A (en) * 1993-03-19 2000-06-13 Sequenom, Inc. DNA sequencing by mass spectrometry via exonuclease degradation
JPH08507926A (ja) * 1993-03-19 1996-08-27 シーケノム・インコーポレーテツド エキソヌクレアーゼ分解を介した質量分析法によるｄｎａ配列決定
US5789165A (en) 1993-05-10 1998-08-04 Nissui Pharmaceutical Co., Ltd. Method and reagent for simultaneously assaying one or more ligands in a group of preselected ligands
US5695941A (en) * 1994-06-22 1997-12-09 The General Hospital Corporation Interaction trap systems for analysis of protein networks
US6428955B1 (en) * 1995-03-17 2002-08-06 Sequenom, Inc. DNA diagnostics based on mass spectrometry
JPH11503611A (ja) 1995-04-11 1999-03-30 トラスティーズ・オブ・ボストン・ユニバーシティ 生体高分子の固相配列決定法
DE69636866D1 (en) * 1995-04-11 2007-03-15 Gen Hospital Corp Reverse "two-hybrid"-systeme
US6017496A (en) * 1995-06-07 2000-01-25 Irori Matrices with memories and uses thereof
US5961923A (en) * 1995-04-25 1999-10-05 Irori Matrices with memories and uses thereof
US5741462A (en) * 1995-04-25 1998-04-21 Irori Remotely programmable matrices with memories
US5751629A (en) * 1995-04-25 1998-05-12 Irori Remotely programmable matrices with memories
US5925562A (en) * 1995-04-25 1999-07-20 Irori Remotely programmable matrices with memories
US6025129A (en) * 1995-04-25 2000-02-15 Irori Remotely programmable matrices with memories and uses thereof
US5874214A (en) * 1995-04-25 1999-02-23 Irori Remotely programmable matrices with memories
US5532379A (en) * 1995-05-05 1996-07-02 Pierce Chemical Company Biotin containing heterobifunctional cleavable compounds
US5625184A (en) * 1995-05-19 1997-04-29 Perseptive Biosystems, Inc. Time-of-flight mass spectrometry analysis of biomolecules
US5777888A (en) * 1995-08-09 1998-07-07 Regents Of The University Of California Systems for generating and analyzing stimulus-response output signal matrices
AU6456496A (en) 1995-08-17 1997-03-12 Hybridon, Inc. Apparatus and process for multi-stage solid-phase synthesis of long-chained organic molecules
US5807525A (en) * 1995-08-17 1998-09-15 Hybridon, Inc. Apparatus and process for multi stage solid phase synthesis of long chained organic molecules
US6146854A (en) 1995-08-31 2000-11-14 Sequenom, Inc. Filtration processes, kits and devices for isolating plasmids
US5654545A (en) * 1995-09-19 1997-08-05 Bruker-Franzen Analytik Gmbh Mass resolution in time-of-flight mass spectrometers with reflectors
US5742049A (en) * 1995-12-21 1998-04-21 Bruker-Franzen Analytik Gmbh Method of improving mass resolution in time-of-flight mass spectrometry
US5641959A (en) * 1995-12-21 1997-06-24 Bruker-Franzen Analytik Gmbh Method for improved mass resolution with a TOF-LD source
JP2000508624A (ja) 1996-03-08 2000-07-11 スミスクライン・ビーチャム・コーポレイション コンビナトリアルライブラリーのスクリーニングの間にタンパク質の化学物質に対する親和性を測定する方法
WO1997037041A2 (en) 1996-03-18 1997-10-09 Sequenom, Inc. Dna sequencing by mass spectrometry
US6475807B1 (en) 1996-04-08 2002-11-05 Smithkline Beecham Corporation Mass-based encoding and qualitative analysis of combinatorial libraries
ES2288760T3 (es) 1996-04-25 2008-01-16 Bioarray Solutions Ltd. Ensamblaje electrocinetico controlado por luz de particulas proximas a superficies.
GB9609262D0 (en) 1996-05-02 1996-07-03 Isis Innovation Peptide library and method
US5777325A (en) * 1996-05-06 1998-07-07 Hewlett-Packard Company Device for time lag focusing time-of-flight mass spectrometry
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US6022688A (en) 1996-05-13 2000-02-08 Sequenom, Inc. Method for dissociating biotin complexes
JP3788519B2 (ja) * 1996-06-28 2006-06-21 カリパー・ライフ・サイエンシズ・インコーポレーテッド 微小スケール流体装置の高処理能力スクリーニングアッセイシステム
IL119029A0 (en) * 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them
US6117631A (en) * 1996-10-29 2000-09-12 Polyprobe, Inc. Detection of antigens via oligonucleotide antibody conjugates
DE69706187T2 (de) 1996-11-06 2002-04-11 Sequenom, Inc. Zusammensetzungen und verfahren zur immobilisierung von nukleinsäure auf festträgern
US20030129589A1 (en) * 1996-11-06 2003-07-10 Hubert Koster Dna diagnostics based on mass spectrometry
US5900481A (en) * 1996-11-06 1999-05-04 Sequenom, Inc. Bead linkers for immobilizing nucleic acids to solid supports
US6133436A (en) * 1996-11-06 2000-10-17 Sequenom, Inc. Beads bound to a solid support and to nucleic acids
US6024925A (en) * 1997-01-23 2000-02-15 Sequenom, Inc. Systems and methods for preparing low volume analyte array elements
ATE259056T1 (de) * 1996-11-06 2004-02-15 Sequenom Inc Verfahren zur massenspektrometrie
US6140053A (en) * 1996-11-06 2000-10-31 Sequenom, Inc. DNA sequencing by mass spectrometry via exonuclease degradation
US5812272A (en) * 1997-01-30 1998-09-22 Hewlett-Packard Company Apparatus and method with tiled light source array for integrated assay sensing
AU748806B2 (en) * 1997-02-04 2002-06-13 Sequenom, Inc. A reversible stoichiometric process for conjugating biomolecules
WO1998054139A1 (de) * 1997-05-30 1998-12-03 Basf Aktiengesellschaft Verfahren zur herstellung substituierter thiopyridine
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
JP2003524364A (ja) * 1997-07-07 2003-08-19 フロリダ ステート ユニバーシティ 分子ターゲットの同定
CN1268979A (zh) 1997-07-22 2000-10-04 拉普吉恩公司 阵列单元的多功能性及其用途
US5972639A (en) * 1997-07-24 1999-10-26 Irori Fluorescence-based assays for measuring cell proliferation
GB9718129D0 (en) * 1997-08-27 1997-10-29 Isis Innovation Branched structures
US6207370B1 (en) * 1997-09-02 2001-03-27 Sequenom, Inc. Diagnostics based on mass spectrometric detection of translated target polypeptides
JP3232052B2 (ja) * 1997-10-31 2001-11-26 松下電器産業株式会社 画像復号化方法
US5922617A (en) * 1997-11-12 1999-07-13 Functional Genetics, Inc. Rapid screening assay methods and devices
US6268131B1 (en) * 1997-12-15 2001-07-31 Sequenom, Inc. Mass spectrometric methods for sequencing nucleic acids
US6083682A (en) * 1997-12-19 2000-07-04 Glaxo Group Limited System and method for solid-phase parallel synthesis of a combinatorial collection of compounds
EP1037972B1 (en) 1997-12-19 2005-09-14 HK Pharmaceuticals, Inc. Non-bacterial cloning in delivery and expression of nucleic acids
WO1999051773A1 (en) 1998-04-03 1999-10-14 Phylos, Inc. Addressable protein arrays
US7094943B2 (en) 1998-04-27 2006-08-22 Hubert Köster Solution phase biopolymer synthesis
US6723564B2 (en) 1998-05-07 2004-04-20 Sequenom, Inc. IR MALDI mass spectrometry of nucleic acids using liquid matrices
CA2332862A1 (en) * 1998-05-15 1999-11-25 Isis Innovation Ltd. Libraries of oligomers labelled with different tags
US6406921B1 (en) * 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
AU755334C (en) 1998-08-25 2004-02-26 University Of Washington Rapid quantitative analysis of proteins or protein function in complex mixtures
US6225061B1 (en) * 1999-03-10 2001-05-01 Sequenom, Inc. Systems and methods for performing reactions in an unsealed environment
US6629040B1 (en) * 1999-03-19 2003-09-30 University Of Washington Isotope distribution encoded tags for protein identification
US20020009394A1 (en) 1999-04-02 2002-01-24 Hubert Koster Automated process line
US6391649B1 (en) * 1999-05-04 2002-05-21 The Rockefeller University Method for the comparative quantitative analysis of proteins and other biological material by isotopic labeling and mass spectroscopy
WO2001018234A1 (en) * 1999-09-03 2001-03-15 Yale University Method to identify gene function using small molecule probes
WO2001018627A2 (en) * 1999-09-06 2001-03-15 National University Of Singapore Method and apparatus for computer automated detection of protein and nucleic acid targets of a chemical compound
CA2387035A1 (en) 1999-10-13 2001-04-19 Sequenom, Inc. Methods for generating databases and databases for identifying polymorphic genetic markers
EP1138781A3 (en) 2000-03-31 2004-07-14 Health Research, Inc. Method for Quantifying DNA binding activity of DNA binding proteins
CA2403296A1 (en) * 2000-04-10 2001-10-18 Benjamin F. Cravatt Proteomic analysis using activity-based probe libraries
US20020037506A1 (en) * 2000-04-18 2002-03-28 Yun Lin Aptamer based two-site binding assay
WO2001094332A1 (en) * 2000-06-02 2001-12-13 Regents Of The University Of California Profiling of protease specificity using combinatorial fluorogenic substrate libraries
ATE423221T1 (de) 2000-06-13 2009-03-15 Univ Boston Verwendung von mass-matched nukleotide in der analyse von oligonukleotidmischungen sowie in der hoch-multiplexen nukleinsäuresequenzierung
EP1309855A2 (en) * 2000-08-14 2003-05-14 Isis Innovation Limited Mass spectrometry
US6531297B2 (en) 2000-10-20 2003-03-11 Applera Corporation Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
JP2004534519A (ja) * 2000-11-17 2004-11-18 アルフレッド イー． スランツ 標的分子機能の決定と薬物リード化合物の同定に関する方法
US6797523B2 (en) * 2000-11-30 2004-09-28 Affinium Pharmaceuticals, Inc. Methods for systematic identification of protein—protein interactions
AU2002230788A1 (en) 2000-12-11 2002-06-24 Hk Pharmaceuticals, Inc. Multiplexed protein expression and activity assay
US6887667B2 (en) 2000-12-28 2005-05-03 Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California Method and apparatus to identify small variations of biomolecules
WO2002063271A2 (en) * 2001-02-05 2002-08-15 Activx Biosciences, Inc. Activity based probe analysis
ATE476654T1 (de) * 2001-03-02 2010-08-15 Activx Biosciences Inc Plattform für protein-profiling
AU2002256060B2 (en) 2001-04-03 2006-12-07 Thermo Finnigan Llc Methods and kits useful for the simplification of complex peptide mixtures
US20020146684A1 (en) * 2001-04-09 2002-10-10 Meldal Morten Peter One dimensional unichemo protection (UCP) in organic synthesis
US7045296B2 (en) 2001-05-08 2006-05-16 Applera Corporation Process for analyzing protein samples
US7183116B2 (en) * 2001-05-14 2007-02-27 The Institute For Systems Biology Methods for isolation and labeling of sample molecules
GB0116143D0 (en) 2001-07-02 2001-08-22 Amersham Pharm Biotech Uk Ltd Chemical capture reagent
JP3935487B2 (ja) * 2001-07-16 2007-06-20 フーベルト・ケスター 捕獲化合物、その収集物、ならびにプロテオームおよび複合組成物の分析方法
EP1319954A1 (en) 2001-12-12 2003-06-18 Centre National de Genotypage Methods for protein analysis using protein capture arrays
EP1468120A1 (en) * 2002-01-28 2004-10-20 MDS Proteomics, Inc. Chemical proteomics
US20030166007A1 (en) * 2002-01-28 2003-09-04 Mds Proteomics Inc. Chemical proteomics
EP1502102B1 (en) * 2002-03-11 2009-01-14 caprotec bioanalytics GmbH Compounds and methods for analyzing the proteome
AU2003249692B2 (en) * 2002-06-03 2008-07-31 The Institute For Systems Biology Methods for quantitative proteome analysis of glycoproteins
WO2003102220A2 (en) * 2002-06-04 2003-12-11 The Institute For Systems Biology Methods for high throughput and quantitative proteome analysis
HUP0202212A2 (hu) * 2002-07-10 2004-04-28 Comgenex Rt. Új kombinatorikus fehérjemarker molekulakönyvtárak, eljárás azok előállítására és alkalmazására
US7473535B2 (en) * 2002-08-20 2009-01-06 The Institute For Systems Biology Chemical reagents and methods for detection and quantification of proteins in complex mixtures
US7135288B2 (en) * 2002-09-27 2006-11-14 Ut-Battelle, Llc Combinatorial synthesis of ceramic materials
ATE489629T1 (de) 2003-01-16 2010-12-15 Caprotec Bioanalytics Gmbh Verfahren zur identifizierung von auf arzneimittel nicht-zielgerichteten proteinen
CN101023181A (zh) * 2004-05-21 2007-08-22 加利福尼亚大学董事会 提高类异戊二烯化合物的产生的方法
AU2006259224B2 (en) 2005-06-16 2012-08-23 Mohammed Saeed Composition and method for inhibiting, preventing, or ameliorating complications associated with ingestion of a medicinal, chemical, or biological substance or agent

Also Published As

Publication number Publication date
AU2004206856C1 (en) 2006-09-07
EP2259068B1 (en) 2013-08-14
WO2004064972A3 (en) 2005-01-27
DE602004030212D1 (de) 2011-01-05
US20100298168A1 (en) 2010-11-25
CA2658334C (en) 2012-07-10
WO2004064972A2 (en) 2004-08-05
US20100248264A1 (en) 2010-09-30
CA2513549A1 (en) 2004-08-05
IL169437A (en) 2010-12-30
JP2006518450A (ja) 2006-08-10
AU2004206856A1 (en) 2004-08-05
JP4741458B2 (ja) 2011-08-03
IL205388A0 (en) 2011-07-31
EP1583972B1 (en) 2010-11-24
HK1080946A1 (en) 2006-05-04
ATE489629T1 (de) 2010-12-15
US20050042771A1 (en) 2005-02-24
US9034798B2 (en) 2015-05-19
CA2513549C (en) 2009-05-05
EP2259068A2 (en) 2010-12-08
JP2008111841A (ja) 2008-05-15
US20060051879A9 (en) 2006-03-09
IL187592A (en) 2010-05-31
AU2004206856B2 (en) 2006-09-07
EP1583972A2 (en) 2005-10-12
CA2658334A1 (en) 2004-08-05
SG153699A1 (en) 2009-07-29
EP2259068A3 (en) 2011-10-19
JP4842914B2 (ja) 2011-12-21
WO2004064972A9 (en) 2004-09-16
AU2004206856A8 (en) 2006-09-07
IL169437A0 (en) 2009-02-11
IL187592A0 (en) 2008-03-20
DK2259068T3 (en) 2013-11-11

Similar Documents

Publication Publication Date Title
AU2004206856B9 (en) Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
US8569481B2 (en) Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
US20040209255A1 (en) Compounds and methods for analyzing the proteome
WO1995035278A1 (en) Methods for synthesizing diverse collections of pyrrolidine compounds
WO2004041752A2 (en) Chemical encoding technology for combinatorial synthesis
AU2006249219B2 (en) Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
US20080070916A1 (en) Dihydropyrancarboxamides and uses thereof
HK1080946B (en) Methods for identifying drug non-target proteins

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: KOSTER, HUBERT

Free format text: FORMER APPLICANT(S): KOSTER, HUBERT; HK PHARMACEUTICALS, INC.

SREP Specification republished
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 19 DEC 2006.

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 04 DEC 2006.

FGA Letters patent sealed or granted (standard patent)
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 04 DEC 2006

PC Assignment registered

Owner name: CAPROTEC BIOANALYTICS GMBH

Free format text: FORMER OWNER WAS: KOSTER, HUBERT

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20 OCT 2010.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20 OCT 2010

MK14 Patent ceased section 143(a) (annual fees not paid) or expired